H.C. Wainwright Reconfirmed Audentes Therapeutics (BOLD) As a “Buy”; They Now Have a Price Target Of $40.0000

May 18, 2018 - By Jason Grubb

Audentes Therapeutics (BOLD) Rating Reaffirmed

The company has just set a target price of $40.0000 on Audentes Therapeutics (BOLD) shares. This is -3.36 % from the previous close. In analysts note shared with investors on Thursday morning, H.C. Wainwright reiterated their “Buy” rating on shares of BOLD.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Coverage

Among 6 analysts covering Audentes Therapeutics (BOLD), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Audentes Therapeutics has $56.0 highest and $26.0 lowest target. $38’s average target is -8.19% below currents $41.39 stock price. Audentes Therapeutics had 11 analyst reports since December 5, 2017 according to SRatingsIntel. H.C. Wainwright maintained Audentes Therapeutics, Inc. (NASDAQ:BOLD) rating on Friday, March 9. H.C. Wainwright has “Buy” rating and $37.0 target. On Tuesday, December 12 the stock rating was initiated by Piper Jaffray with “Buy”. H.C. Wainwright maintained the shares of BOLD in report on Thursday, January 11 with “Buy” rating. The firm earned “Buy” rating on Thursday, January 4 by H.C. Wainwright. Mizuho initiated Audentes Therapeutics, Inc. (NASDAQ:BOLD) rating on Monday, February 12. Mizuho has “Hold” rating and $26.0 target. H.C. Wainwright maintained the shares of BOLD in report on Wednesday, May 2 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, February 7. The stock of Audentes Therapeutics, Inc. (NASDAQ:BOLD) has “Buy” rating given on Thursday, January 4 by William Blair.

The stock increased 21.91% or $7.44 during the last trading session, reaching $41.39. About 1.87 million shares traded or 404.37% up from the average. Audentes Therapeutics, Inc. (BOLD) has risen 72.67% since May 18, 2017 and is uptrending. It has outperformed by 61.12% the S&P500.

Analysts await Audentes Therapeutics, Inc. (NASDAQ:BOLD) to report earnings on August, 9. They expect $-0.79 EPS, up 9.20 % or $0.08 from last year’s $-0.87 per share. After $-0.74 actual EPS reported by Audentes Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.76 % negative EPS growth.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company has market cap of $1.52 billion. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It currently has negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.

More notable recent Audentes Therapeutics, Inc. (NASDAQ:BOLD) news were published by: Streetinsider.com which released: “Audentes Therapeutics (BOLD) Plunges 7.5% After Reporting Data from Phase 1/2 Clinical Trial of AT132 in patients …” on May 16, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” published on May 17, 2018, Seekingalpha.com published: “Audentes Therapeutics: Key Program Updates” on May 12, 2018. More interesting news about Audentes Therapeutics, Inc. (NASDAQ:BOLD) were released by: Streetinsider.com and their article: “Audentes Therapeutics (BOLD) Announces Continuing Positive Data from First Dose Cohort of ASPIRO” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Genomic Medicine: Catch The Gene Therapy Wave” with publication date: May 14, 2018.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: